ZIMMER BIOMET HOLDINGS, INC. (ZBH) Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Devices
Zimmer Biomet Holdings, Inc. NYSE:ZBH Healthcare · Medical - Devices
Mkt Cap $18.8B
Div Yield 0.97%
AH Close $98.56 +0.00% vs close
AH Close $98.56 +0.00% vs close
Mkt Cap $18.8B
Div Yield 0.97%
All Press Release SEC Filings News
Press Release
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Zimmer Biomet and THINK Surgical announced a multi-year extension of their Limited Exclusive Distribution and Supply Agreement following a successful initial term.
Under the extension, Zimmer Biomet will continue exclusively distributing a customized version of THINK's wireless, handheld TMINI Miniature Robotic System compatible with the Persona Knee System.
The deal supports Zimmer Biomet's strategy of offering a broad robotics ecosystem for orthopedic surgeons, though no financial terms were disclosed.
• 12d ago AI analysis › Press Release
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
Zimmer Biomet announced its Q3 2026 earnings conference call will be webcast on November 4, 2026, at 8:30 a.m. ET.
The quarterly results news release will be issued the same day at 6:30 a.m. ET, with a live audio webcast on the company's investor relations site.
This is a scheduling notice only; no financial figures were disclosed.
• 19d ago AI analysis › Press Release
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Zimmer Biomet announced three executive promotions effective October 1, 2026, to streamline its Americas and Global Business Group organizations.
Gary Campbell was promoted to President, Americas; Brian Hatcher to President of Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data.
The company also noted that Group President Kevin Thornal will leave the company on September 30, 2026, following a transition period.
• 1mo ago AI analysis › Press Release
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
Zimmer Biomet's Board of Directors approved a quarterly cash dividend of $0.24 per share for the third quarter of 2026.
The dividend is payable on October 30, 2026 to stockholders of record at the close of business on September 30, 2026.
• 1mo ago AI analysis › SEC Filing ⚠ 5
ZBH: 8-K · other
Zimmer Biomet filed an 8-K under Item 8.01 solely to recast segment-level financial information from its 2025 Form 10-K. The recast reflects second-quarter 2026 changes in how leaders reporting to the chief operating decision maker run the business: Foot and Ankle results in EMEA and Asia Pacific now roll into the Americas segment, and centralized R&D and global marketing expenses moved into Americas segment results.
The company stressed the filing is not an amendment or restatement and consolidated results are unchanged: FY2025 net sales of $8,231.5 million (up 7.2%), net earnings of $705.1 million, and diluted EPS of $3.55. The recast MD&A repeats the 2026 outlook of 2.5% to 4.5% net sales growth with higher expected operating profit.
The auditor (PCAOB ID 238, Zimmer Biomet's auditor since 2000) updated its opinion date to August 5, 2026 solely for the segment composition changes in Note 18. Context from the recast data includes $7,519.1 million of debt against $591.9 million of cash, and roughly $1.65 billion paid in 2025 for the Paragon 28 and Monogram acquisitions.
SEC 8-K • 2mo ago SEC Filing ⚠ 7
ZBH: 10-Q · periodic report
Zimmer Biomet's Q2 2026 net sales rose 4.8% year-over-year to $2,177.0 million, with net earnings up roughly 30% to $198.3 million and diluted EPS of $1.03 versus $0.77 a year ago. First-half sales grew 7.0% to $4,263.7 million, led by the Paragon 28 acquisition, ROSA Robot and bone cement sales, and new product introductions.
The company reaffirmed 2026 guidance of 3.9% to 4.9% net sales growth and expects operating profit to increase, helped by an approximately $30 million benefit from probable U.S. tariff refunds, restructuring savings, and lower acquisition costs. Capital returns stayed aggressive: $500.8 million of stock was repurchased in the first half under the $1.5 billion authorization, leaving $1,003.1 million, alongside a $0.24 quarterly dividend.
After quarter-end, Zimmer Biomet acquired a business and signed a merger agreement adding pain management and surgical technology for roughly $245 million upfront plus up to $210 million in contingent consideration. Watch items include IRS proposed adjustments for 2013-2019, China distributor litigation, up to $720 million of contingent consideration through 2031, and $7,479.0 million of debt against $410.0 million in cash.
SEC 10-Q • 2mo ago AI analysis › Press Release
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Zimmer Biomet reported Q2 revenue of $2.18 billion, up 4.8% year-over-year, with adjusted EPS of $2.07, flat compared to the prior year.
The company raised its full-year 2026 guidance, projecting revenue growth of 3.9% to 4.9% and adjusted EPS between $8.47 and $8.59, driven by strong first-half performance and market momentum.
Operational highlights include generating $308.3 million in free cash flow and receiving FDA 510(k) clearance for the next-generation ROSA Shoulder System, alongside an increased share repurchase authorization of up to $1 billion.
• 2mo ago AI analysis › Press Release
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
Zimmer Biomet appointed Chintan Desai as president of the Asia Pacific region, effective immediately.
Desai joins from Alcon, where he served as VP and GM of International Growth and Export Markets, and brings nearly three decades of experience from GE Healthcare.
He replaces Sang Yi, who will depart on August 28 after 13 years with the company.
• 3mo ago AI analysis › Press Release
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
Zimmer Biomet scheduled its second quarter 2026 earnings conference call for August 5, 2026, at 8:30 a.m. ET.
The full financial results press release will be issued earlier that morning at 6:30 a.m. ET.
A live audio webcast will be accessible via the company's investor relations website, with a replay available following the call.
• 3mo ago AI analysis › SEC Filing
ZBH: 8-K · debt financing
Zimmer Biomet Holdings, Inc. entered into new unsecured revolving credit agreements to replace its existing credit facilities. The new financing comprises a $1.5 billion five-year facility maturing on June 26, 2031, and a $1.25 billion 364-day facility maturing on June 25, 2027. JPMorgan Chase Bank, N.A. serves as the administrative agent for both agreements, which will be used for general corporate purposes and include an option to increase the five-year facility by up to $750 million.
The company terminated its previous five-year and 364-day credit agreements dated June 27, 2025, with no principal balance outstanding at the time of termination. Zimmer Biomet paid approximately $0.4 million in termination fees associated with the previous agreements. All existing letters of credit issued under the old five-year agreement were transitioned to the new Five-Year Revolving Credit Agreement.
Both new credit agreements contain customary covenants, requiring the company to maintain a maximum consolidated indebtedness to consolidated EBITDA ratio of 4.5 to 1.0. This leverage ratio may increase to 5.0 to 1.0 if the company undertakes a qualified material acquisition. Borrowings will bear interest at floating rates based on an adjusted Term SOFR or an alternate base rate.
SEC 8-K • 3mo ago AI analysis › Press Release
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Zimmer Biomet management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
The session is scheduled for 10:40 a.m. ET and will be available via live audio webcast on the company's Investor Relations website.
This is a standard investor relations appearance with no new operational or financial disclosures.
• 4mo ago AI analysis › SEC Filing
ZBH: 8-K · proxy statement
Zimmer Biomet Holdings, Inc. held its annual meeting of shareholders on May 22, 2026, where shareholders elected ten directors for one-year terms ending in 2027.
Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 and approved the compensation of named executive officers on an advisory basis.
The company rejected a shareholder proposal calling for an independent board chairman, with 137,043,058 votes against and 31,288,886 votes for the measure.
SEC 8-K • 4mo ago Press Release
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet declared a quarterly cash dividend of $0.24 per share for the second quarter of 2026.
The payment is scheduled for July 31, 2026, to stockholders of record as of June 25, 2026.
This is a routine maintenance of the existing dividend policy with no change in rate.
• 5mo ago AI analysis › Press Release
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
prnewswire.com • 5mo ago Press Release
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
Zimmer Biomet announced that members of its management team will participate in the Bank of America Securities 2026 Health Care Conference.
The fireside chat is scheduled for Wednesday, May 13, 2026, at 8:40 a.m. PT.
A live audio webcast will be available on the Zimmer Biomet Investor Relations website, with a replay to follow the event.
• 5mo ago AI analysis › SEC Filing ⚠ 4
ZBH: 10-Q · periodic report
Zimmer Biomet reported first-quarter net sales of $2.09 billion, a 9.3% increase year-over-year, driven by the Paragon 28 acquisition, favorable foreign currency exchange rates, and market growth. Net earnings rose 31% to $238.1 million, or $1.22 per diluted share, aided by a $30 million favorable adjustment related to probable U.S. tariff refunds and lower restructuring charges compared to the prior year.
The company repurchased $250.1 million of common stock during the quarter and authorized a new $1.5 billion share repurchase program. Cash and cash equivalents decreased to $424.2 million from $591.9 million at year-end 2025, while the company maintained $2.5 billion in available liquidity under its credit facilities and held total debt of $7.47 billion.
For the full year 2026, management expects net sales growth of 2.5% to 4.5%, leveraging new product introductions and market growth while offsetting headwinds from pricing pressure and changes in the U.S. go-to-market strategy. The ongoing restructuring plan is expected to reduce annual operating expenses by approximately $175 million by the end of 2027.
SEC 10-Q • 5mo ago AI analysis › Press Release ● Major ⚠ 1
Zimmer Biomet Announces First Quarter 2026 Financial Results
Zimmer Biomet reported Q1 net sales of $2.09 billion, up 9.3% reported and 2.9% organic constant currency, driven by healthy end markets and new product momentum.
Adjusted diluted EPS increased 15.5% to $2.09, leading the company to raise its full-year adjusted EPS guidance to $8.40-$8.55.
The company returned $250 million to shareholders through share repurchases and generated $245.9 million in free cash flow.
• 5mo ago AI analysis › Press Release ⚠ 1
Zimmer Biomet Announces Chief Financial Officer Transition
Zimmer Biomet announced that CFO Suketu Upadhyay is departing the company effective immediately to pursue a new professional opportunity.
Paul Stellato, currently Controller and Chief Accounting Officer, has been appointed interim CFO while the company conducts a search for a permanent successor.
CEO Ivan Tornos expressed confidence in Stellato's ability to provide continuity, citing his 20 years of financial and investor relations experience.
• 5mo ago AI analysis › 
